503a semaglutide Empower Semaglutide Compounding Update: What 503A
Description
In this trial, 10 patients with NASH were given 20 mg of GS-0976 daily
Monitoring: Patients on these medications should be monitored for symptoms related to thyroid or pancreatic issues
Avoid high-fiber foods
They are not meant to treat chronic conditions or provide long-term care
